Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 134.38B, Vertex Pharmaceuticals(VRTX) trades at $519.24. The stock has a price-to-earnings ratio of 31.30.
On 2026-07-06, Vertex Pharmaceuticals(VRTX) stock traded between a low of $512.34 and a high of $529.99. Shares are currently priced at $519.24, which is +1.3% above the low and -2.0% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.51M, against a daily average of 2.51M.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $529.99 and a 52-week low of $362.50.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $529.99 and a 52-week low of $362.50.
VRTX News
Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceuticals (CRNX) for...
Vertex Pharmaceuticals has agreed to purchase Crinetics Pharmaceuticals for $10 billion. brian snyder / Reuters Vertex Pharmaceuticals VRTX 0.29 %increase; up...
Analyst ratings
81%
of 36 ratingsMore VRTX News
Technology Vertex Pharma Makes A $10 Billion Deal; Biotech Stock Doubles Licensing Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledg...
Vertex Pharmaceuticals Incorporated (VRTX) and Crinetics Pharmaceuticals, Inc. (CRNX), a global pharmaceutical company focused on the discovery, development and...
Key Points Vertex's business is growing modestly but there's much more growth potentially on the horizon. The stock's valuation has risen significantly and it...
Vertex Pharmaceuticals (VRTX) signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the tre...
Key Points Vertex Pharmaceuticals' recent sell-off was overdone. Nvidia's growth story and dominance in the AI chip market are simply too good to ignore. Alib...
...
Vertex Pharmaceuticals (NasdaqGS:VRTX) received FDA approval for CASGEVY gene therapy in children as young as 2 years old with sickle cell disease and transfusi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.